ArticleAntimicrobial agents and chemotherapy2002
Mechanisms of decreased susceptibility to cefpodoxime in Escherichia coli.
Article in Antimicrobial agents and chemotherapy, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 89 citations in OpenAlex.
- Inferring Amoxicillin-Clavulanate Susceptibility From Ampicillin-Sulbactam Susceptibility Against Common Enterobacterales Species.Open forum infectious diseases · 2025Article
- Prevalence and virulence profiles of ESBL-producing Escherichia coli in urinary and blood infections in South Korea.Folia microbiologica · 2025Article
- Serovar and sequence type distribution and phenotypic and genotypic antimicrobial resistance ofMicrobiology spectrum · 2024Article
- MAST® D72C test: a novel option for ESBL, AmpC and carbapenemase detection.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Article
- Antibacterial Activity of Boron Compounds Against Biofilm-Forming Pathogens.Biological trace element research · 2024Article
- Biofilm-forming antimicrobial-resistant pathogenicHeliyon · 2023Article
- Evaluation of presence of clone ST131 and biofilm formation in ESBL producing and non-producing Escherichia coli strains.Molecular biology reports · 2023Article
- Characterization of Increased Extracellular Vesicle-Mediated Tigecycline Resistance inPharmaceutics · 2023Article
- Prevalence, antimicrobial resistance, and staphylococcal toxin genes of blaVeterinary medicine and science · 2023Article
- Assessment of virulence factors and antimicrobial resistance among the Pseudomonas aeruginosa strains isolated from animal meat and carcass samples.Veterinary medicine and science · 2023Article
- Clonal Dissemination of Extended-Spectrum Cephalosporin-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- D-Mannoside FimH Inhibitors as Non-Antibiotic Alternatives for UropathogenicAntibiotics (Basel, Switzerland) · 2021Article
- Molecular Characterization of Antibiotic Resistance Associated withIranian journal of pathology · 2021Article
- Multiple Drug Resistance Patterns in Various Phylogenetic Groups of Hospital-Acquired UropathogenicAntibiotics (Basel, Switzerland) · 2020Article
- Genetic Features ofFrontiers in microbiology · 2019Article
- Do the clonally differentThe Indian journal of medical research · 2018Article
- Extended-spectrum β-lactamase & carbapenemase-producing Gram-negative bacilli in neonates from a tertiary care centre in Dibrugarh, Assam, India.The Indian journal of medical research · 2018Article
- Incidence and molecular characterization of the extended spectrum beta lactamase-producing Escherichia coli isolated from urinary tract infections in Eastern Saudi Arabia.Saudi medical journal · 2017Article
- Genetic Investigation of Beta-Lactam Associated Antibiotic Resistance AmongThe open microbiology journal · 2017Article
- The MAST® D68C test: an interesting tool for detecting extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cefpodoxime is one of five antimicrobial agents recommended by the National Committee for Clinical Laboratory Standards for screening isolates of Klebsiella spp. and Escherichia coli for extended-spectrum beta-lactamase (ESBL) production. In a prior study, we noted that among 131 E. coli isolates for which the MIC of at least one extended-spectrum cephalosporin (ESC) or aztreonam was > or =2 micro g/ml (suggesting the presence of ESBL production), there were 59 isolates (45.0%) for which the MIC of cefpodoxime was 2 to 4 micro g/ml (i.e., a positive ESBL screening test), but the MICs of ceftazidime, cefotaxime, and ceftriaxone were < or =1 micro g/ml (below the ESBL screening breakpoint). Thus, the results appeared to be false-positive ESBL screening tests. These 59 isolates were divided into five phenotypic groups based on the susceptibility patterns of the organisms to a variety of beta-lactam agents and further characterized. The first group (32 isolates) all produced a TEM-1 beta-lactamase, and changes in the major outer membrane proteins were detected in representative strains. The second group (18 isolates) lacked bla(TEM) but showed a number of porin changes; some also showed a modest elevation in production of the AmpC chromosomal beta-lactamase. In the third phenotypic group (seven isolates) all expressed an OXA-30 beta-lactamase. Some also harbored altered porins. The two remaining phenotypes each had a distinct pattern of porin changes with or without beta-lactamase production. These data indicate that several factors are associated with decreased susceptibility to cefpodoxime in E. coli, but none of the mechanisms are related to ESBL production. Current screening methods produced false-positive ESBL results for these isolates. Such isolates should not be classified as containing ESBLs, nor should interpretations of ESCs or aztreonam susceptibility be changed to resistant on test reports for these isolates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.